Biomedical ETF (512290) rose over 2%, Zhifei Biological rose more than 7%

Zhifei Biological rose more than 7%, biomedical ETF (512290) rose more than 2%, and the turnover exceeded 135 million yuan.

Anxin Securities stated that the supervision of the drug -centered drug research and development concept, and multiple guidance principles are expected to promote the long -term innovation and development of the industry.On August 9, the relevant departments' approval center issued the three major guidelines such as "Patient-centric Clinical Test benefits-Risk Evaluation Technical Guidance Principles (Draft for Opinions)" and other guidelines.The concept helps to improve the current domestic clinical trial efficiency. It can avoid adverse effects on clinical trials such as public health prevention and control, and it is expected to accelerate the progress of clinical development of related drugs in the future.

- END -